Comparative Pharmacology
Head-to-head clinical analysis: CALCIPOTRIENE versus HECTOROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPOTRIENE versus HECTOROL.
CALCIPOTRIENE vs HECTOROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
None Documented
None Documented
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog